Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001649553-25-000111
Filing Date
2025-06-24
Accepted
2025-06-24 10:00:35
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10063
2 LIMITED POWER OF ATTORNEY sc13g_ex24.htm EX-24 2382
3 JOINT FILING AGREEMENT pcsa_sc13g-ex99.htm EX-99 1711
  Complete submission text file 0001649553-25-000111.txt   15965
Mailing Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076
Business Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 443-776-3133
Processa Pharmaceuticals, Inc. (Subject) CIK: 0001533743 (see all company filings)

EIN.: 451539785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90420 | Film No.: 251067009
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 345-949-8080
CVI Investments, Inc. (Filed by) CIK: 0001649553 (see all company filings)

EIN.: 981253664 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G